At ECTRIMS, we had the pleasure of speaking with Marianna Cortese about her research in multiple sclerosis, including her interest in the microbiome.
Browsing: Demyelinating disease
In this interview, we spoke with Bruce Trapp about how his team identified a new subtype of multiple sclerosis, termed myelocortical multiple sclerosis.
Novartis (Basel, Switzerland) have announced US FDA and EMA filing acceptance for siponimod, a new drug developed to treat secondary progressive multiple sclerosis in adults.
The MS-STAT2 trial is underway, with researchers investigating simvastatin as a potential treatment option for individuals with secondary progressive multiple sclerosis.
A Phase II clinical trial of ibudilast has revealed that the drug decreases progression of brain atrophy in patients with progressive multiple sclerosis.
A team from Cleveland Clinic (OH, USA) has identified a new subtype of multiple sclerosis, termed myelocortical multiple sclerosis.
The US FDA has accepted for filing a resubmission of the New Drug Application for cladribine tablets by Merck; this could be a potential treatment for patients with relapsing forms of multiple sclerosis.